A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity

HaEmek Medical Center, Israel

Status: Completed

Conditions: Obesity; Apixaban; Anticoagulant

Treatments: Diagnostic Test: Anti Xa levels

Study type: Observational

Funder types: Other

Identifiers

NCT03893591

0004-19

Details and patient eligibility

About

A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.

Enrollment: 82 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hospitalized Patients on Steady State level of Apixaban, based on the data given in the hospital ward . A level of Steady State is received within two days of treatment.

Exclusion criteria

• Anasarca
• acute renal failure

Trial design

82 participants in 2 patient groups

Body mass index below 35

Treatment:

Diagnostic Test: Anti Xa levels

Body mass index 35 and above

Treatment:

Diagnostic Test: Anti Xa levels